Gazyva (Obinutuzumab)

obinutuzumab 1 g/40 mL injection, 40 mL vial · INJECTION · PBS code 12204H

STREAMLINED

What it costs

AU$4299.24 PBS-determined price per pack

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2020-12-01.
• Repeats: 8.
• PBS program: IP.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)

For combination use with venetoclax treatment cycles 1 to 6 inclusive in first-line therapy

The condition must be untreated; AND

The treatment must be in combination with PBS-subsidised venetoclax; AND

The treatment must not be in combination with acalabrutinib.

Sponsor: Roche Products Pty Ltd ABN 70 000 132 865

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.